Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer

M J Schiewer; L M Morey; C J Burd; D E Merry; S-M Ho; K E Knudsen

doi:10.1038/onc.2008.446

journal article Dec 15, 2008

Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer

M J Schiewer L M Morey C J Burd D E Merry S-M Ho K E Knudsen

Oncogene Vol. 28 No. 7 pp. 1016-1027 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/onc.2008.446

Topics

No keywords indexed for this article. Browse by subject →

References

78

[1]

Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW et al. (1999). Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 91: 1869–1876. 10.1093/jnci/91.21.1869

[2]

Balk SP, Knudsen KE . (2008). AR, the cell cycle, and prostate cancer. Nucl Recept Signal 6: e001. 10.1621/nrs.06001

[3]

Bienvenu F, Gascan H, Coqueret O . (2001). Cyclin D1 represses STAT3 activation through a Cdk4-independent mechanism. J Biol Chem 276: 16840–16847. 10.1074/jbc.m100795200

[4]

Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ et al. (1995). Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 52: 459–467. 10.1016/0960-0760(95)00005-k

[5]

Burd CJ, Petre CE, Moghadam H, Wilson EM, Knudsen KE . (2005). Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Mol Endocrinol 19: 607–620. 10.1210/me.2004-0266

[6]

Burnstein KL . (2005). Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 95: 657–669. 10.1002/jcb.20460

[7]

Chen C, Okayama H . (1987). High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7: 2745–2752. 10.1128/mcb.7.8.2745

[8]

Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS . (2006). Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 66: 10613–10620. 10.1158/0008-5472.can-06-0028

[9]

Cheng M, Sexl V, Sherr CJ, Roussel MF . (1998). Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA 95: 1091–1096. 10.1073/pnas.95.3.1091

[10]

Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM . (2007). Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 120: 719–733. 10.1002/ijc.22365

[11]

Coqueret O . (2002). Linking cyclins to transcriptional control. Gene 299: 35–55. 10.1016/s0378-1119(02)01055-7

[12]

Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D et al. (1999). Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59: 2551–2556.

[13]

Esquenet M, Swinnen JV, Heyns W, Verhoeven G . (1995). Triiodothyronine modulates growth, secretory function and androgen receptor concentration in the prostatic carcinoma cell line LNCaP. Mol Cell Endocrinol 109: 105–111. 10.1016/0303-7207(95)03490-x

[14]

Ewen ME, Lamb J . (2004). The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med 10: 158–162. 10.1016/j.molmed.2004.02.005

[15]

Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM . (1993). Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73: 487–497. 10.1016/0092-8674(93)90136-e

[16]

Feldman BJ, Feldman D . (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34–45. 10.1038/35094009

[17]

Franke TF, Kaplan DR, Cantley LC . (1997). PI3K: downstream AKTion blocks apoptosis. Cell 88: 435–437. 10.1016/s0092-8674(00)81883-8

[18]

Fu M, Rao M, Bouras T, Wang C, Wu K, Zhang X et al. (2005). Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. J Biol Chem 280: 16934–16941. 10.1074/jbc.m500403200

[19]

Fu M, Wang C, Li Z, Sakamaki T, Pestell RG . (2004). Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145: 5439–5447. 10.1210/en.2004-0959

[20]

Ganter B, Fu S, Lipsick JS . (1998). D-type cyclins repress transcriptional activation by the v-Myb but not the c-Myb DNA-binding domain. EMBO J 17: 255–268. 10.1093/emboj/17.1.255

[21]

Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ et al. (2005). Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer 12: 119–134. 10.1677/erc.1.00835

[22]

Gottschalk AR, Doan A, Nakamura JL, Haas-Kogan DA, Stokoe D . (2005). Inhibition of phosphatidylinositol-3-kinase causes cell death through a protein kinase B (PKB)-dependent mechanism and growth arrest through a PKB-independent mechanism. Int J Radiat Oncol Biol Phys 61: 1183–1188. 10.1016/j.ijrobp.2004.12.024

[23]

Gregory CW, Johnson Jr RT, Mohler JL, French FS, Wilson EM . (2001). Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61: 2892–2898.

[24]

Hadaschik BA, Gleave ME . (2007). Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol 25: 413–419. 10.1016/j.urolonc.2007.05.010

[25]

Hess-Wilson JK, Daly HK, Zagorski WA, Montville CP, Knudsen KE . (2006). Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Res 66: 11998–12008. 10.1158/0008-5472.can-06-2249

[26]

Efficient p53 Activation and Apoptosis by Simultaneous Disruption of Binding to MDM2 and MDMX

Baoli Hu, Daniele M. Gilkes, Jiandong Chen

Cancer Research 2007 10.1158/0008-5472.can-07-1140

[27]

Inoue K, Sherr CJ . (1998). Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol Cell Biol 18: 1590–1600. 10.1128/mcb.18.3.1590

[28]

James MK, Ray A, Leznova D, Blain SW . (2008). Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity. Mol Cell Biol 28: 498–510. 10.1128/mcb.02171-06

[29]

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ . (2007). Cancer statistics, 2007. CA Cancer J Clin 57: 43–66. 10.3322/canjclin.57.1.43

[30]

Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW . (1979). Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16–23.

[31]

Kato A, Ota S, Bamba H, Wong RM, Ohmura E, Imai Y et al. (1998). Regulation of cyclin D-dependent kinase activity in rat liver regeneration. Biochem Biophys Res Commun 245: 70–74. 10.1006/bbrc.1998.8377

[32]

Knudsen KE . (2006). The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Div 1: 15. 10.1186/1747-1028-1-15

[33]

Knudsen KE, Arden KC, Cavenee WK . (1998). Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem 273: 20213–20222. 10.1074/jbc.273.32.20213

[34]

Knudsen KE, Cavenee WK, Arden KC . (1999). D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res 59: 2297–2301.

[35]

Li J, Fu J, Toumazou C, Yoon HG, Wong J . (2006). A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. Mol Endocrinol 20: 776–785. 10.1210/me.2005-0298

[36]

Li J, Lin Q, Wang W, Wade P, Wong J . (2002). Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. Genes Dev 16: 687–692. 10.1101/gad.962502

[37]

Lilja H, Ulmert D, Vickers AJ . (2008). Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8: 268–278. 10.1038/nrc2351

[38]

Lin HM, Zhao L, Cheng SY . (2002). Cyclin D1 is a ligand-independent co-repressor for thyroid hormone receptors. J Biol Chem 277: 28733–28741. 10.1074/jbc.m203380200

[39]

Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA et al. (2008). Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68: 6407–6415. 10.1158/0008-5472.can-07-5997

[40]

Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF et al. (1992). Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71: 323–334. 10.1016/0092-8674(92)90360-o

[41]

Maucher A, von Angerer E . (1993). Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours. J Cancer Res Clin Oncol 119: 669–674. 10.1007/bf01215986

[42]

McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR . (1999). Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59: 4291–4296.

[43]

Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ et al. (2007a). Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 67: 7991–7995. 10.1158/0008-5472.can-07-2043

[44]

Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT et al. (2007b). Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20: 538–544. 10.1038/modpathol.3800769

[45]

Minamiguchi K, Kawada M, Ohba S, Takamoto K, Ishizuka M . (2004). Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth. Mol Cell Endocrinol 214: 175–187. 10.1016/j.mce.2003.10.060

[46]

Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS et al. (2008). Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68: 4447–4454. 10.1158/0008-5472.can-08-0249

[47]

Mullany LK, White P, Hanse EA, Nelsen CJ, Goggin MM, Mullany JE et al. (2008). Distinct proliferative and transcriptional effects of the D-type cyclins in vivo. Cell Cycle 7: 2215–2224. 10.4161/cc.7.14.6274

[48]

Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J et al. (1997). Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17: 5338–5347. 10.1128/mcb.17.9.5338

[49]

Olshavsky NA, Groh EM, Comstock CE, Morey LM, Wang Y, Revelo MP et al. (2008). Cyclin D3 action in androgen receptor regulation and prostate cancer. Oncogene 27: 3111–3121. 10.1038/sj.onc.1210981

[50]

Parry D, Mahony D, Wills K, Lees E . (1999). Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol 19: 1775–1783. 10.1128/mcb.19.3.1775

Showing 50 of 78 references

Metrics

19

Citations

78

References

Details

Published: Dec 15, 2008
Vol/Issue: 28(7)
Pages: 1016-1027
License: View

Authors

Cite This Article

M J Schiewer, L M Morey, C J Burd, et al. (2008). Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. Oncogene, 28(7), 1016-1027. https://doi.org/10.1038/onc.2008.446

Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer

You May Also Like